Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>Key 3Q25 takeaways include: 1) following the closing of the Medsphere acquisition, management remains focused on tapping into the company's existing inpatient EHR and RCM relationships across small- and mid-sized hospitals 2) the recently acquired MapApp enhances CCLD's hospital analytics capabilities, particularly as it relates to RCM performance, and management plans to leverage/integrate proprietary AI capabilities, and link MapApp analytics to specific CCLD solutions, thereby enhancing win rates with prospective clients 3) our model calls for continued growth in operating cash flow reflecting rising revenues and ongoing margin expansion, with ample capacity to continue to reinvest for growth and capitalize on incremental M&A opportunities and 4) from a structural standpoint, incremental deals likely include asset purchases at attractive valuations financed through combination of upfront internally-generated cash and tapping the company's credit facility at favorable terms/rates to preserve balance sheet flexibility, minimize shareholder dilution, and optimize accretion.</li></ul>

Key 3Q25 takeaways include: 1) following the closing of the Medsphere acquisition, management remains focused on tapping into the company's existing inpatient EHR and RCM relationships across small- and mid-sized hospitals 2) the recently acquired MapApp enhances CCLD's hospital analytics capabilities, particularly as it relates to RCM performance, and management plans to leverage/integrate proprietary AI capabilities, and link MapApp analytics to specific CCLD solutions, thereby enhancing win rates with prospective clients 3) our model calls for continued growth in operating cash flow reflecting rising revenues and ongoing margin expansion, with ample capacity to continue to reinvest for growth and capitalize on incremental M&A opportunities and 4) from a structural standpoint, incremental deals likely include asset purchases at attractive valuations financed through combination of upfront internally-generated cash and tapping the company's credit facility at favorable terms/rates to preserve balance sheet flexibility, minimize shareholder dilution, and optimize accretion.

CareCloud

CCLD: 3Q25 Earnings